Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway

Journal of Cellular and Molecular Medicine
Jian ChenQianqian Zhang

Abstract

Tumour growth depends on a continual supply of the nutrients and oxygen, which are offered by tumour angiogenesis. Our previous study showed that dipalmitoylphosphatidic acid (DPPA), a bioactive phospholipid, inhibits the growth of triple-negative breast cancer cells. However, its direct effect on angiogenesis remains unknown. Our work showed that DPPA significantly suppressed vascular growth in the chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models. Meanwhile, tumour angiogenesis and tumour growth were inhibited by DPPA in the tumour tissues of an experimental breast cancer model, a subcutaneous xenograft mouse model and a genetically engineered spontaneous breast cancer mouse model (MMTV-PyMT). Furthermore, DPPA directly inhibited the proliferation, migration and tube formation of vascular endothelial cells. The anti-angiogenic effect of DPPA was regulated by the inhibition of Cut-like homeobox1 (CUX1), which transcriptionally inhibited fibroblast growth factor 1 (FGF1), leading to the downregulation of hepatocyte growth factor (HGF). This work first demonstrates that DPPA directly inhibits angiogenesis in cancer development. Our previous work along with this study suggest that DPPA functions as an...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Apr 1, 2003·Molecular and Cellular Biology·Mary TruscottAlain Nepveu
Jun 29, 2004·Journal of Translational Medicine·Anita TandleSteven K Libutti
Jun 2, 2007·Journal of Cellular Biochemistry·Kyoung-Jin OhJoong-Soo Han
Mar 4, 2008·Gene·Laurent Sansregret, Alain Nepveu
Mar 17, 2009·Experimental & Molecular Medicine·Hye-Jin ChoiJoong-Soo Han
Oct 19, 2010·Journal of Oncology·Adhemar Longatto FilhoFernando C Schmitt
May 24, 2012·Expert Opinion on Investigational Drugs·William J Gradishar
Aug 13, 2013·Cancer Science·Kyoko HidaYasuhiro Hida
Jan 30, 2014·Japanese Journal of Clinical Oncology·Elham Fakhrejahani, Masakazu Toi
Apr 29, 2014·Journal of Liposome Research·Mariam KhvedelidzeIngolf Bernhardt
Sep 17, 2014·Journal of Visualized Experiments : JoVE·Katie L DeCicco-SkinnerJonathan S Wiest
Sep 25, 2014·Endocrine-related Cancer·Sebastian KrugPatrick Michl
May 23, 2017·International Journal of Biological Sciences·Qian-Qian ZhangLijing Wang
Aug 26, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hai-Jian SunLi-Ying Qiu

❮ Previous
Next ❯

Citations

Oct 28, 2019·Melanoma Research·René Delgado-HernándezWim Vanden Berghe
Jul 4, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J PengR Zeng
Sep 5, 2019·International Journal of Molecular Sciences·Lei ChenYu-Dong Cai
Feb 6, 2022·Journal of Cancer Research and Clinical Oncology·Cynthia KohlThomas Papathemelis

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
PCR
electrophoresis
transgenic
xenografts

Software Mentioned

IPP
Quantity One

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.